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Abstract
Background: High rates of loss to follow-up (LTFU) are undermining rapidly expanding antiretroviral treatment
(ART) services in sub-Saharan Africa. The intelligent dispensing of ART (iDART) is an open-source electronic
pharmacy system that provides an efficient means of generating lists of patients who have failed to pick-up
medication. We determined the duration of pharmacy delay that optimally identified true LTFU.
Methods: We conducted a retrospective cross-sectional study of a community-based ART cohort in Cape Town,
South Africa. We used iDART to identify groups of patients known to be still enrolled in the cohort on the 1
st of
April 2008 that had failed to pick-up medication for periods of ≥ 6, ≥ 12, ≥ 18 and ≥ 24 weeks. We defined true
LTFU as confirmed failure to pick up medication for 3 months since last attendance. We then assessed short-term
and long-term outcomes using a prospectively maintained database and patient records.
Results: On the date of the survey, 2548 patients were registered as receiving ART but of these 85 patients (3.3%)
were found to be true LTFU. The numbers of individuals (proportion of the cohort) identified by iDART as having
failed to collect medication for periods of ≥6, ≥12, ≥18 and ≥24 weeks were 560 (22%), 194 (8%), 117 (5%) and 80
(3%), respectively. The sensitivities of these pharmacy delays for detecting true LTFU were 100%, 100%, 62.4% and
47.1%, respectively. The corresponding specificities were 80.7%, 95.6%, 97.4% and 98.4%. Thus, the optimal delay
was ≥12 weeks since last attendance at this clinic (equivalent to 8 weeks since medication ran out). Pharmacy
delays were also found to be significantly associated with LTFU and death one year later.
Conclusions: The iDART electronic pharmacy system can be used to detect patients potentially LTFU and who
require recall. Using a short a cut-off period was too non-specific for LTFU and would require the tracing of very
large numbers of patients. Conversely prolonged delays were too insensitive. Of the periods assessed, a ≥12 weeks
delay appeared optimal. This system requires prospective evaluation to further refine its utility.
Background
Antiretroviral therapy (ART) has become much more
widely available in resource-limited countries with a
high burden of HIV/AIDS. Four million people were
estimated to be receiving ART in low- or middle-
income countries by the end of 2008, of whom 2.9 mil-
lion were in sub-Saharan Africa and 701,000 were in
South Africa alone [1]. Success in scale-up, however, is
being tempered by the fact that escalating case-loads of
patients attending individual clinics present a major
challenge to the effective retention of patients in care.
Low levels of retention particularly threaten to under-
mine ART programmes in sub-Saharan Africa. Here,
8%-26% of patients die in the first year of ART [2] and
a further proportion may be lost to follow-up (LTFU),
with combined attrition rates of approximately 40% at
2 years in many programmes [3]. Identifying and tracing
patients who are potentially LTFU is essential to maintain
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needed for this are very limited and development of
information systems that permit the most effective
deployment of these resources would be of great
benefit.
Pharmacy-based records of collection of medication by
patients can be used as a system for early identification
of patients who are potentially LTFU [4]. iDART, for
example, is a computerized software system that
requires no licence and is freely available to download
at URL http://www.cell-life.org/idart/download. This
system allows clinic management teams to generate lists
of patients who failed to pick up medication and who
can then be traced in the community. However, it is not
known what delay of pharmacy pick-ups optimally iden-
tifies true programme losses to follow-up.
We therefore conducted a study at a community-
based ART clinic in Cape Town, South Africa, using
pharmacy dispensing data recorded by the iDART sys-
tem to examine the relationship between the duration of
the delay in scheduled pharmacy pick-ups of medication
and LTFU. We hypothesized ap r i o r ithat too short a
delay would be too non-specific and would inadvertently
lead to the tracing of large numbers of patients who
were not LTFU. Conversely, we hypothesized that too
prolonged a delay would fail to identify a proportion of
patients LTFU who did require tracing.
Methods
Setting
This is a well characterized ART service [5-7] in a poor
peri-urban area in Cape Town, South Africa. The Des-
mond Tutu HIV Centre began providing ART at this
service in September 2002 and by April 2008, 3384
patients had started ART. The clinic is supported by an
on-site pharmacy staffed by pharmacists and pharmacy
assistants. Patients routinely pick up drug supplies for
one month, although for various reasons a minority may
be given a 2-months supply. Electronic pharmacy pick-
up data by patients has been recorded since the intro-
duction of iDART in February 2007.
Data sources
Data for this analysis were obtained from the following
3 sources: (1) a prospectively maintained ART cohort
database that is updated weekly and contains outcomes
derived from patient notes and data forms supplied by
the ART service; (2) iDART electronic pharmacy
records of ART regimens and dispensing dates; (3) indi-
vidual patient records.
Definitions
In keeping with the majority of other literature [3],
true losses to follow up (LTFU) were patients who had
failed to attend the clinic for ≥12 weeks and who were
not known to have died or been transferred to another
ART clinic. Death referred to all-cause mortality noti-
fied by peer counselors after home visits, relatives/
family members and hospitals. Previous data suggest
that differentiation between deaths and LTFU using
these sources is possible [6,7]. Transfers-out referred
to patients receiving ART who s ec a r ew a st r a n s f e r r e d
to another clinic.
Study design
This was a retrospective cross-sectional survey of
patients enrolled on treatment on the 1
st of April 2008,
with ascertainment of the reasons for failure to collect
medication both at the time of the survey as well as one
year after the survey. The ART cohort database was first
used to define the patients who were still enrolled and
should be receiving ART in the cohort. Within this
active treatment cohort, patients were identified as
potential LTFU using the iDART dispensing system
based on time since last attendance at the clinic to col-
lect medication. Patients failing to collect medication
were categorized into four groups based on the duration
of the delay: i) ≥6 weeks ii) ≥12 weeks and iii) ≥18
weeks and iv) ≥24 weeks.
Patient records and the cohort database were then
used to determine the reasons for failure to pick up
medication by these 4 patient groups. The outcomes of
the treatment cohort who were included in the cross-
sectional survey were assessed at that time (short-term
outcomes). In addition, the outcomes of these same
individuals were determined at a time-point one year
later (long-term outcomes). The relationship between
the period of delay in pharmacy pick-ups and the out-
comes of the patients was then determined.
Ethical approval for this study was obtained from the
Research Ethics Committees of the University of Cape
Town and the International Union Against Tuberculosis
and Lung disease.
Statistical analyses
The study cohort was defined as patients known to be
receiving ART at the 1
st of April 2008. Descriptive sta-
tistics were used to characterize the cohort. Proportions
were used for categorical variables. Means, medians,
standard deviations and interquartile ranges were used
for continuous variables as appropriate. The proportion
of each of the true outcomes of patients at each of the
delayed periods and associated confidence intervals were
determined. For each period of delay, we calculated the
sensitivity, specificity, positive predictive value and nega-
tive predictive value for predicting LTFU and associated
confidence intervals. Confidence intervals were calcu-
lated using exact binomial techniques. Statistical analysis
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Station, Texas, USA).
Results
Treatment cohort
Between September 2002 when the clinic was first
opened and the time of the cross-sectional survey in
April 2008, a total of 3384 patients had initiated ART.
During this period, 334 (9.9%) were LTFU, 249 (7.4%)
were transferred out, and 253 (7.5%) had died. This left
2548 patients who were registered as still receiving ART
and therefore formed the patient cohort at the time of
this cross-sectional survey.
The characteristics of the patients in the study cohort
(n = 2548) at the time of ART initiation were as follows:
a majority (86%) of patients were ART-naïve, most were
female (67%) and the median age was 32 years (inter-
quartile range [IQR], 27-38). Immunodeficiency was
advanced with a median blood CD4 lymphocyte count
of 124 cells/μL (IQR, 63-192). Disease was categorized
as World Health Organization (WHO) clinical stage III
in 52.4% and stage IV in 21.5%. These patients had been
receiving ART within this service for a median of 1.9
years (IQR, 1.0-2.9).
Patients identified as potentially LTFU
The iDART pharmacy tracking system was used to iden-
tify groups of patients within cohort that failed to collect
ART for periods of ≥6, ≥12, ≥18 and ≥24 weeks. Those
missing pharmacy visits for ≥6 weeks represented 22% of
the whole cohort and the number of patients was 2.9
times higher than that identified using the ≥12 weeks cut-
off. More prolonged pharmacy delay cut-offs identified
substantially fewer patients as potential LTFU (Figure 1).
True outcomes of patients identified by the iDART system
We next explored the underlying reasons for pharmacy
delays other than LTFU (Table 1). Of the large number
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Figure 1 Proportions of the antiretroviral treatment (ART) cohort identified as having had missed pharmacy visits for periods of ≥ 6,
≥ 12, ≥ 18 or ≥ 24 weeks using the iDART pharmacy tracking system. Absolute numbers of patients in each category are shown above
each bar.
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delay, just 15.2% were true LTFU and a large majority
of the remaining patients were actively receiving ART
(Table 1). Of patients identified using the ≥ 12, ≥ 18
and ≥ 24 weeks cut-offs, the proportions of patients
with each outcome were very similar. The proportions
who were true LTFU ranged from 44-50%. Most other
patients were actually still in care and either receiving
treatment (range, 23-25%) or had temporarily inter-
rupted treatment (18-22%). A smaller proportion of
these patients were found to have died (4%-6%).
Sensitivity and specificity of pharmacy delays
In total, there were 85 patients who were true LTFU,
representing 3.3% of the overall cohort. We calculated
the sensitivities, specificities and positive and negative
predictive values of the ≥6, ≥12, ≥18 and ≥24 week
iDART pharmacy delay periods (Table 2). Delays of the
≥6a n d≥12 weeks were 100% sensitivity for true LTFU
whereas more prolonged delays showed much lower
sensitivities. However, the specificity of the ≥12 week
delay was substantially greater than that of the ≥6 week
delay (Table 2).
Outcomes at one year
We next determined the status of the same 4 groups of
patients at a time-point one year after the cross-
sectional survey (Figure 2) and compared these with the
outcomes of patients who had no pharmacy delay at the
time of the survey (n = 1988). Twenty two patients who
were originally LTFU had returned to care within the
year of follow-up. However, much higher proportions of
those with delays of ≥6, ≥12, ≥18 and ≥24 weeks were
designated as LTFU one year later compared to patients
with no pharmacy delay [27.0% (151/560), 49.5% (96/
194), 48.7% (57/117) and 52.5% (42/80) versus 9.5%
(189/1988), respectively P < 0.001 for all comparisons]
(Figure 2). Similarly, higher proportions of those with
pharmacy delays had died after one year [3.8% (21/560),
7.7% (15/194), 10.3% (12/117) and 8.8% (7/80) versus
0.02% (34/1988), respectively; P < 0.02 for comparisons
of ≥12 weeks group and ≥18 weeks groups with no
delay group]. Thus, detection of pharmacy delays was
prognostic of poor long-term outcomes with regard to
LTFU and mortality.
Discussion
Practical solutions are urgently needed to address the
challenge of low rates of patient retention in many ART
programmes in sub-Saharan Africa [8]. A critical issue is
the need to rapidly identify patients who have missed
appointments so that patient tracing interventions can
be deployed to re-engage patients as soon as possible in
care. Using the iDART computerized pharmacy tracking
Table 1 Outcomes of patients identified iDART pharmacy tracking system using four different delays in pharmacy
pick-ups.
Weeks delay of pharmacy pick-ups
≥6 ≥12 ≥18 ≥24
N Proportion (95% CI) N Proportion (95% CI) N Proportion (95% CI) N Proportion (95% CI)
True LTFU 85 15.2 (12.2-18.2) 85 43.8 (36.8-50.9) 53 45.3 (36.1-54.5) 40 50.0 (38.8-61.2)
Deaths 10 1.8 (0.7-2.9) 8 4.1 (1.3-6.9) 7 6.0 (1.6-10.3) 3 3.8 (-0.5-8.0)
Transfers-out 19 3.4 (1.9-4.9) 14 7.2 (3.5-10.9) 5 4.3 (0.6-8.0) 5 6.3 (0.8-11.7)
On treatment 404 72.1 (68.4-75.9) 45 23.2 (17.2-29.2) 29 24.8 (16.8-32.7) 18 22.5 (13.1-31.9)
In clinic off treatment 42 7.5 (5.3-9.7) 42 21.6 (15.8-27.5) 23 19.7 (12.3-27.0) 14 17.5 (9.0-26.0)
Total 560 22.0 (20.4-23.6) 194 7.6 (6.6-8.6) 117 4.6 (3.8-5.4) 80 3.1 (2.5-3.8)
LTFU, loss to follow-up; N, number; CI, confidence intervals.
Table 2 Raw data, sensitivity, specificity and positive predictive value and negative predictive value for the four
different delays in pharmacy pick-ups
Delays of
pharmacy
pick-ups,
weeks*
a b c d Sensitivity
%(95% CI)
Specificity
%(95% CI)
PPV
% (95% CI)
NPV
% (95% CI)
≥6 85 475 0 1988 100.0 (95.8-100.0) 80.7 (79.1-82.3) 15.2 (12.2-18.2) 100.0 (99.8 -100.0)
≥12 85 109 0 2354 100.0 (95.8-100.0) 95.6 (94.7-96.4) 43.8 (36.8-50.9) 100.0 (99.8-100.0)
≥18 53 64 32 2399 62.4 (51.2-72.6) 97.4 (96.7-98.0) 45.3 (36.1-54.5) 98.7 (98.1-99.1)
≥24 40 40 45 2423 47.1 (36.1-58.2) 98.4 (97.8-98.8) 50.0 (38.8-61.2) 98.2 (97.6-98.7)
*Pharmacy delays detected by iDART were compared to true LTFU status; a, true positives; b, false positives; c, false negatives; d, true negatives; PPV, positive
predictive value; NPV, negative predictive value; %, percentage and CI, confidence intervals.
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pharmacy pick-ups that best identified true LTFU. A ≥6
weeks cut-off would result in the tracing of very large
numbers of patients of whom only 15% (approximately
1 in 7) would be true LTFU. Use of cut-offs of ≥12, ≥18
and ≥24 weeks, however, would greatly reduce the num-
bers of patients who would require tracing, but the ≥12
weeks cut-off was found to be optimal with a sensitivity
of 100.0% and a specificity of 95.6%.
Patients who are LTFU should ideally be re-engaged
back in care as soon as possible and thus we included
within this analysis an examination of a short delay in
pharmacy pick-ups (≥6 weeks, typically representing 2
weeks since medication supply ran out) which had high
sensitivity. However, one fifth of the cohort had failed to
collect medication for ≥6 weeks and yet only a small
minority was actually LTFU. Shorter delays than this
period would be even more non-specific and the asso-
ciated work-load associated with tracing all these
patients would not be feasible in this service.
In keeping with most other literature from sub-
Saharan Africa, we defined true LTFU as patients who
had failed to attend for a period of ≥3m o n t h s[ 3 ] .
However, we hypothesized that use of pharmacy delays
longer than this period might identify smaller groups of
patients with a high yield of LTFU, thereby minimizing
the numbers of patients needing to be traced. Indeed,
use of increasingly prolonged cut-offs of ≥12, ≥18 and
≥24 weeks was associated with sequential reductions in
the numbers of patients that would require tracing.
However, more prolonged delays of ≥18 and ≥24 weeks
had substantially reduced sensitivity for LTFU despite
higher specificity. Thus, on the basis of trade-off
between sensitivity and specificity, we identified the ≥12
weeks delay as the optimal cut-off among the four peri-
ods assessed. This is entirely consistent with the optimal
delay for identifying LTFU found in a study conducted
in Zambia (56 days since medication ran out) [9].
We also ascertained outcomes of each of the same 4
groups of patients one year after the time of the cross-
sectional study and compared them with the outcomes
of patients for whom no pharmacy delay was detected.
Approximately one quarter of patients with pharmacy
delays of ≥6 weeks and one half of the patients with
pharmacy delays of ≥12, ≥18 and ≥24 weeks were LTFU
at this time-point compared to just 9.9% of those with
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outcome are shown.
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those with pharmacy delays had died by one year fol-
low-up. This indicates that the detection of pharmacy
delays using the iDART system can be used to identify
groups of patients who have poor long-term retention
and increased mortality risk.
Computerised systems are used to track patients effi-
ciently and are a potential solution for the rapid identifi-
cation of patients potentially LTFU. However, the utility
of these systems depends on user friendliness, afford-
ability, sustainability, stability, security and data owner-
ship. Sites across Africa employ a wide range of
electronic information systems to identify patients to be
potentially traced [10,11]. The iDART system is non-
commercial, user friendly, requires no license and is
freely available to download at URL http://www.cell-life.
org/idart/download. However, it requires an uninter-
rupted electricity supply and requires a computer, bar-
code printer, barcode reader and offsite back-up such a
flash memory stick, cell phone, email or internet con-
nection. This system has advantages over other known
electronic information systems used in Haiti, Kenya,
Malawi and Zambia in terms of its low cost, user friend-
liness, minimal staff training requirements and sustain-
ability [11].
The strengths of this study include the fact that
iDART is a relatively simple retention measure that
could potentially be implemented in settings that are
able to support the required infrastructure. In 2009,
the system was being successfully used in over 35 sites,
mainly in South Africa but also in other countries. The
cohort studied is within the South African public sec-
tor system and is very well characterized with good
quality data on patient outcomes. Limitations include
the retrospective design of the study and that the
impact of any existing interventions active within this
clinic on one year outcomes is unknown. Although
this initial cross-sectional study explores the associa-
tion between LTFU and one key variable (i.e. delays in
pharmacy pick-ups), multiple factors may be associated
with LTFU and these factors may vary with duration
of ART. The important findings of this initial cross-
sectional study have been used to devise a long-term
prospective study in which the complexities of predict-
ing LTFU can be further refined. This may enable
more sophisticated algorithms to identify patients who
are potentially LTFU to be developed in due course.
Outcomes may differ in clinics with different ART dis-
pensing patterns. Although this study suggests that
≥12 weeks since last clinic attendance to pick-up medi-
cation is the optimal definition of LTFU, the choice of
optimal delay in other settings may depend on the
resources available.
Conclusions
In summary, the iDART electronic pharmacy system can
best be used to identify patients potentially LTFU and
with high risk of long-term LTFU or death by detecting
those who have failed to collect medication for a period
of ≥12 weeks. Approximately one half of such patients
were true LTFU and use of this system may be used to
trigger patient tracing. Use of this system should be
evaluated prospectively in tandem with patient tracing
interventions to assess the effects on both short-term
and long-term outcomes.
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